Jack Derwin
Markets and finance correspondent
Jack has worked as a business reporter for the better part of a decade, filing from Mexico, Spain, New Zealand and the Pacific. He has previously reported for The Asahi Shimbun, the second largest newspaper in the world, Business Insider and 7News amongst others.
Contact Jack via email or Signal.
Shops like Optiver, Susquehanna International Group and IMC Trading are on the ascendancy in Australia and posting big profits off the back of extreme volatility.
At this year's Macquarie Conference, CEOs tackled tariffs, shifting consumers and M&A hopes — with a side of burrito bravado from Guzman y Gomez.
The impacts of Donald Trump's trade agenda dominated the first day of Macquarie's Australia conference, while Labor's election win barely rated a mention.
The hedge fund manager says there have not been redemptions as a result of its bungled biotech bet, and in fact it has experienced inflows.
Minotaur Capital is shorting the tech giant — and backing developers — as a legal defeat threatens one of Apple’s crown jewels.
The fund manager, which controls $3 billion in assets, has filed regulatory paperwork for a new private credit vehicle.
Regal Partners is under pressure after its $220 million Opthea stake soured, dragging down its share price, unsettling investors and derailing its ASX 300 hopes.
The hedge fund's CEO has moved to quell concerns after it emerged that portfolio managers and traders are facing a steep financial hit from a disastrous biotech bet.
The sudden resignation of two independent directors at the troubled miner has incensed investors, super funds and proxy advisory firms alike.
Today's sudden resignation of two independent directors came just hours after Capital Brief revealed increasing pressure for accountability over the company's scandals.
An influential proxy advisor has recommended shareholders vote against an Illuka director because of her presence on the board of Mineral Resources.
Private credit veteran Ryan Donnar says discipline is key as new lenders flood the market and risks mount in a sector chasing fast growth and high returns.
ASX retailers ranging from ecommerce play Cettire to furniture retailer Nick Scali and more could be hit by second order effects from a US trade war with China.
Another day, another volatile session. And with no sign that Trump's unpredictability or the resulting market mayhem will end anytime soon, investors and businesses are getting weary.
Trump’s 90-day tariff truce has restored some calm, but economists warn the uncertainty will still weigh heavily on business investment.
Sukhinder Singh Cassidy is on track to be the second highest paid CEO on the ASX this year behind Macquarie's Shemara Wikramanayake.
"End of the free trade era" or "no biggie"? Donald Trump may have finally revealed his sweeping global tariffs, but their impact on Australia and the rest of the world won't be clear for some time.
De Petro has exited Canaccord after nine years as the broker trims its Melbourne ECM team.
The MD of small cap advisor Oakley Capital Partners, owned by Adam Blumenthal's family trust, says the former broker has 'no involvement' in the business.
The resolve of the financial tech provider appears to be softening as it faces opposition from brokers and prominent investment banks over a controversial bill.
Investors are losing faith in the existence of a 'Trump put' to prop up markets. The question is whether that holds if sharemarkets keep falling.
Australian stocks saw another substantial drop today after further declines on Wall St as the US president continues to swerve on tariffs. But is the selloff overdone?
Antipodes Partners and others are increasingly relying on non-traditional sources of information to get an investing edge — and a crop of providers are eager to find it for them.
The media frenzy surrounding Richard White didn't really feature as the WiseTech founder fronted analysts to discuss his return and the company's performance.
Australia's peak stockbroking body has claimed there is no legal basis for its members to cover the company's cost blowout as tensions flare.
Ramsay Healthcare and St John of God Health Care have emerged as potential players in the race to save Healthscope.
After exiting its first investment in just 12 months, Scarcity’s ex-Pinnacle founders are now looking to build on their momentum.
Shares in the once popular defence stock are down 75% from their peak, with military spending cuts in the US and new fibre optic technology cited as factors.
The arrival of Chemist Warehouse on the ASX via a merger with Sigma Healthcare is both the end of a long journey for its founders and the start of a major expansion plan.
The essential service provider at the heart of the Australian sharemarket blindsided brokers, and even the ASX itself, with its latest cost-saving move.
